Viewing Study NCT04041050

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:50 PM
Ignite Modification Date: 2026-03-31 @ 10:12 AM
Study NCT ID: NCT04041050
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-02-14
First Post: 2019-07-30
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
Sponsor: AbbVie
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Myeloproliferative Neoplasm View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Myeloproliferative Neoplasm (MPN) View
None Chronic myelomonocytic leukemia (CMML) View
None Polycythemia Vera (PV) View
None Essential Thrombocythemia (ET) View
None Myelofibrosis (MF) View
None cancer View
None navitoclax View
None ruxolitinib View